Not a good buy right now for an impatient entry: price is technically extended (RSI overbought) and sitting just below near-term resistance, with no strong catalyst or proprietary buy signal supporting chasing strength.
Better odds come from a pullback toward the pivot (~26.01) or a clean breakout above ~27.35 with follow-through; at 27.2 pre-market, the risk/reward is not attractive.
Momentum: MACD histogram +0.211 and expanding indicates positive momentum still building.
Condition: RSI_6 at 81.51 = overbought; odds of a near-term pause/pullback are elevated.
Levels: Pivot 26.01 (key support/mean reversion area); Resistance R1 27.35 then R2 28.17. With pre-market at 27.2, price is close to R1 (limited upside before resistance).
Pattern-based forward look: Similar-pattern stats imply modest upside potential (next day +0.57%, next week +0.71%, next month +4.35%) but probability shown is only 40%, not a high-conviction setup.
Upcoming earnings event (2026-02-09 pre-market) can act as a catalyst if results surprise positively.
Sector/Street tone improving versus prior bearishness (recent upgrade from Sell to Neutral in comparable coverage set).
Neutral/Negative Catalysts
while price is approaching resistance (R1 ~27.
makes immediate upside less compelling.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 22,450,103; YoY change shown as +0.00% (flat).
Net income: 9,466,149; YoY change shown as +0.00% (flat).
EPS: 0.77; YoY change shown as +0.00% (flat).
Takeaway: profitability is present, but the data provided indicates no growth acceleration heading into the next earnings catalyst.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent rating trend: shifting less negative but still cautious—Goldman upgraded to Neutral from Sell (PT EUR 35.50), and JPMorgan reiterated Neutral while raising PT (EUR 36 from EUR 33).
Wall Street pros (bull case): constructive broader bank-sector outlook focused on growth/efficiency and capital deployment; price targets moved up.
Wall Street cons (bear case): ratings remain Neutral (not Buy), implying upside is viewed as limited/less compelling at current levels.
Wall Street analysts forecast CBK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBK is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CBK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBK is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 26.260
Low
0
Averages
0
High
0
0
Current: 26.260
Low
0
Averages
0
High
0
JPMorgan
Kian Abouhossein
Neutral
maintain
AI Analysis
2026-01-20
Reason
JPMorgan
Kian Abouhossein
Price Target
AI Analysis
2026-01-20
maintain
Neutral
Reason
JPMorgan analyst Kian Abouhossein raised the firm's price target on Commerzbank to EUR 36 from EUR 33 and keeps a Neutral rating on the shares.
Goldman Sachs
Sell -> Neutral
upgrade
$35.50
2025-12-03
Reason
Goldman Sachs
Price Target
$35.50
2025-12-03
upgrade
Sell -> Neutral
Reason
Goldman Sachs upgraded Commerzbank to Neutral from Sell with an unchanged price target of EUR 35.50. The firm adjusted ratings in the European bank group as part of its outlook for 2026. Goldman remains remain constructive on the outlook for the sector, saying investor focus is shifting from interest rates and credit to growth and efficiency. It thinks capital deployment will remain key for shareholder value creation.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CBK
